Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

18 results
Display

Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B

Lee YS, Kim BK, Lee HJ, Dan J

In Fanconi syndrome, hypophosphatemic osteomalacia is caused by proximal renal tubule dysfunction which leads to impaired reabsorption of amino acids, glucose, urate, and phosphate. We present a rare case of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multiple Stress Fractures Related to Low-dose Adefovir Dipivoxil Treatment in a Patient with Chronic Hepatitis B: A Case Report

Park CH, Ahn HS, Lee DC

Stress fractures typically result from repeated abnormal mechanical loading to the bones. In particular, multiple stress fractures may occur in patients with systemic disease, such as rheumatoid arthritis, osteoporosis, or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus

Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS

BACKGROUND/AIMS: Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Cases of Hypophosphatemic Osteomalacia After Long-term Low Dose Adefovir Therapy in Chronic Hepatitis B and Literature Review

Jeong HJ, Lee JM, Lee TH, Lee JY, Kim HB, Heo MH, Choi G, Chae JN, Kim JM, Kim SH, Kwon KY

  • KMID: 2391956
  • J Bone Metab.
  • 2014 Feb;21(1):76-83.
Adefovir dipivoxil (ADV) is a nucleotide used as long-term therapy of chronic hepatitis B. Many published reports have shown that long-term high-dose therapy with adefovir can be associated with proximal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Factors for Delayed Virologic Response of Adefovir Add-on Therapy in Lamivudine-resistant Chronic Hepatitis B

Baek AR, Kim DY, Kim YS, Kim SG, Kim JH, Kim MS, Kim TJ, Lee YN, Lee SH, Jeong SW, Jang JY, Kim HS, Kim BS

  • KMID: 2317691
  • Soonchunhyang Med Sci.
  • 2013 Jun;19(1):10-16.
OBJECTIVE: Lamivudine (LAM) is the first nucleoside analog approved for chronic hepatitis B (CHB) patients, but acquired mutation of the reverse transcriptase of the virus during long-term therapy is limiting...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Naive Chronic Hepatitis B Patients at 48 Weeks

Wang LC, Chen EQ, Zhu XF, Xiong ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H

  • KMID: 2284239
  • Gut Liver.
  • 2011 Dec;5(4):478-485.
BACKGROUND/AIMS: To reveal possible factors predicting the effect of adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and optimize the utilization of ADV. METHODS: In total, 168 treatment-naive CHB patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B

Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH

  • KMID: 2284188
  • Gut Liver.
  • 2010 Jun;4(2):212-218.
BACKGROUND/AIMS: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A case of hypophosphatemic osteomalacia associated with low-dose adefovir dipivoxil treatment

Yoo KD, Jeong JH, Cho SK, Kim GH, Choi HS, Kim DS, Jun JB

  • KMID: 2142948
  • Korean J Med.
  • 2010 Feb;78(2):261-265.
Adefovir dipivoxil (ADV) effectively inhibits lamivudine-resistant hepatitis B virus replication. Hypophosphatemia and elevated serum creatinine are ADV-related nephrotoxicity caused by high-dose ADV. Hypophosphatemic osteomalacia is very rare and is induced...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients

Jung HW, Choi MS, Kim KH, Park SH, Yeon KK, Lee JH, Koh KC, Paik SW, Yoo BC

BACKGROUNDS/AIMS: It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Therapeutic Efficacy of Adefovir Dipivoxil in Korean Children and Adolescents with Chronic Hepatitis B who have Developed Lamivudine Resistance

Hwang SK, Park SM, Choe BH, Kim JM, Kim JO, Kim YM, Lee JH, Cho MH, Tak WY, Kweon YO

  • KMID: 2275347
  • Korean J Pediatr Gastroenterol Nutr.
  • 2008 Sep;11(2):143-149.
PURPOSE: To estimate the long-term therapeutic efficacy and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B who have developed lamivudine resistance. METHODS: Sixteen patients (12 boys and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus

Kim KM, Choi WB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ

The purpose of this prospective study was to evaluate the efficacy and safety of adefovir dipivoxil with or without ongoing lamivudine in decompensated lamivudine-resistant chronic hepatitis B patients. Forty-six hepatitis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Adefovir Dipivoxil in Patients with Decompensated Liver Cirrhosis with Lamivudine Resistance Compared to Patients with Compensated Liver Disease

Moon W, Choi MS, Moon YM, Paik SW, Lee JH, Koh KC, Yoo BC, Rhee JC, Shim SG

  • KMID: 760590
  • Korean J Hepatol.
  • 2005 Jun;11(2):125-134.
BACKGROUND/AIMS: Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV). However, little is known about its role in Korean patients with decompensated liver cirrhosis. We retrospectively...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dose and Treatment Duration of Regimen

Kweon YO

  • KMID: 760573
  • Korean J Hepatol.
  • 2005 Mar;11(1):13-16.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Indication of Drug Therapy in Patients with Chronic Hepatitis B

Cho M

  • KMID: 760571
  • Korean J Hepatol.
  • 2005 Mar;11(1):1-8.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Antiviral Therapy for Chronic Hepatitis B

Lim YS, Suh DJ

During the past decade, major breakthroughs have been achieved in treatment of chronic hepatitis B. Currently, three therapeutic agents are approved for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-viral Treatment of Chronic Hepatitis B

Seo DJ

Patients with chronic hepatitis B virus (HBV) infection are at risk for development of liver cirrhosis and hepatocellular carcinoma. The goal of antiviral therapy for chronic hepatitis B is the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Application and Efficacy of Adefovir Dipivoxil in Hepatitis B Virus-assoicated Chronic Liver Diseases

Cho YK, Kim BI

  • KMID: 1112185
  • Korean J Gastroenterol.
  • 2003 Nov;42(5):357-362.
In therapy of chronic hepatitis B, there are new and exciting developments in antivirals such as nucleotide analogues. Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of New Anti-viral Agent in the Treatment of Chronic Hepatitis B

Kim YS

  • KMID: 2240153
  • Korean J Gastroenterol.
  • 2002 Aug;40(2):81-87.
The aims of antiviral therapy for chronic hepatitis B are to sustain suppression of hepatitis B virus (HBV) replication and to achieve remission of liver disease activity. Currently, interferon- and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr